Effects of complement factor D deficiency on the renal disease of MRL/lpr mice

Kidney International

Volumn 65, Issue 1, 2004, Pages 129-138

  Elliott, Margaret K ^b   Jarmi, Tambi ^b   Ruiz, Phil ^b   Xu, Yuanyuan ^b   Holers, V Michael ^b   Gilkeson, Gary S ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b NONE

Author keywords

Animal models; Complement alternative pathway; Lupus nephritis

Indexed keywords

AUTOANTIBODY; COMPLEMENT FACTOR D; COMPLEMENT MEMBRANE ATTACK COMPLEX; GLUTARALDEHYDE; IMMUNOGLOBULIN G;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY DETECTION; ARTICLE; COMPLEMENT ACTIVATION; COMPLEMENT ALTERNATIVE PATHWAY; COMPLEMENT DEFICIENCY; CONTROLLED STUDY; CREATININE BLOOD LEVEL; ENZYME LINKED IMMUNOSORBENT ASSAY; HAPLOTYPE; KIDNEY DISEASE; LUPUS ERYTHEMATOSUS NEPHRITIS; MAJOR HISTOCOMPATIBILITY COMPLEX; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEINURIA; SYSTEMIC LUPUS ERYTHEMATOSUS; TISSUE SECTION;

EID: 0347992784     PISSN: 00852538     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1523-1755.2004.00371.x     Document Type: Article

References (46)

1. PRODINGER WM, WURZNER R, ERDEI A, DIERICH MP: Complement, in Fundamental Immunology, 4th ed, edited by Paul WE, Philadelphia, Lippincott-Raven, 1999, pp 967-995
2. ARORA M, ARORA R, TIWARI SC, et al: Expression of complement regulatory proteins in diffuse proliferative glomerulonephritis. Lupus 9:127-131, 2000
3. BIESECKER G, KATZ S, KOFFLER D: Renal localization of the membrane attack complex in systemic lupus erythematosus nephritis. J Exp Med 154:1779-1794, 1981
4. FALK RJ, DALMASSO AP, KIM Y, et al: Neoantigen of the polymerized ninth component of complement. Characterization of a monoclonal antibody and immunohistochemical localization in renal disease. J Clin Invest 72:560-573, 1983
5. WYATT RJ, MCADAMS AJ, FORRISTAL J, et al: Glomerular deposition of complement-control proteins in acute and chronic glomerulonephritis. Kidney Int 16:505-512, 1979
6. HOCHBERG MC, BOYD RE, AHEARN JM, et al: Systemic lupus erythematosus: A review of clinico-laboratory features and immunogenetic markers in 150 patients with emphasis on demographic subsets. Medicine (Baltimore) 64:285-295, 1985
7. MANZI S, RAIRIE JE, CARPENTER AB, et al: Sensitivity and specificity of plasma and urine complement split products as indicators of lupus disease activity. Arthritis Rheum 39:1178-1188, 1996
8. KERR LD, ADELSBERG BR, SCHULMAN P, Spiera H: Factor B activation products in patients with systemic lupus erythematosus. A marker of severe disease activity. Arthritis Rheum 32:1406-1413, 1989
9. YOSHIOKA T, ICHIKAWA I: Glomerular dysfunction induced by polymorphonuclear leukocyte-derived reactive oxygen species. Am J Physiol 257:F53-F59, 1989
10. SCHREINER GF: The role of the macrophage in glomerular injury. Semin Nephrol 11:268-275, 1991
11. THEOFILOPOULOS AN, DIXON FJ: Murine models of systemic lupus erythematosus. Adv Immunol 37:269-390, 1985
12. WATANABE H, GARNIER G, CIRCOLO A, et al: Modulation of renal disease in MRL/lpr mice genetically deficient in the alternative complement pathway factor B. J Immunol 164:786-794, 2000
13. WATSON ML, RAO JK, GILKESON GS, et al: Genetic analysis of MRL-lpr mice: Relationship of the Fas apoptosis gene to disease manifestations and renal disease-modifying loci. J Exp Med 176:1645-1656, 1992
14. VIDAL S, KONO DH, THEOFILOPOULOS AN: Loci predisposing to autoimmunity in MRL-Fas lpr and C57BL/6-Faslpr mice. J Clin Invest 101:696-702, 1998
15. XU Y, MA M, IPPOLITO GC, et al: Complement activation in factor D-deficient mice. Proc Natl Acad Sci USA 98:14577-14582, 2001
16. FOLEY S, LI B, DEHOFF M, et al: Mouse Crry/p65 is a regulator of the alternative pathway of complement activation. Eur J Immunol 23:1381-1384, 1993
17. BERNSTEIN KA, VALERIO RD, LEFKOWITH JB: Glomerular binding activity in MRL lpr serum consists of antibodies that bind to a DNA/histone/type IV collagen complex. J Immunol 154:2424-2433, 1995
18. SEKINE H, REILLY CM, MOLANO ID, et al: Complement component C3 is not required for full expression of immune complex glomerulonephritis in MRL/lpr mice. J Immunol 166:6444-6451, 2001
19. FUNG M, LOUBSER PG, UNDAR A, et al: Inhibition of complement, neutrophil, and platelet activation by an anti-factor D monoclonal antibody in simulated cardiopulmonary bypass circuits. J Thorac Cardiovasc Surg 122:113-122, 2001
20. KALLI KR, HSU P, FEARON DT: Therapeutic uses of recombinant complement protein inhibitors. Springer Semin Immunopathol 15:417-431, 1994
21. MOORE FD, JR.: Therapeutic regulation of the complement system in acute injury states. Adv Immunol 56:267-299, 1994
22. PASCUAL M, CATANA E, WHITE T, et al: Inhibition of complement alternative pathway in mice with Fab antibody to recombinant adipsin/factor D. Eur J Immunol 23:1389-1392, 1993
23. TANHEHCO EJ, KILGORE KS, LIFF DA, et al: The anti-factor D antibody. MAb 166-32, inhibits the alternative pathway of the human complement system. Transplant Proc 31:2168-2171, 1999
24. THURMAN JM, LJUBANOVIC D, EDELSTEIN CL, et al: Lack of a functional alternative complement pathway ameliorates ischemic acute renal failure in mice. J Immunol 170:1517-1523, 2003
25. DE VRIES B, MATTHIJSEN RA, WOLFS TG, et al: Inhibition of complement factor C5 protects against renal ischemia-reperfusion injury: Inhibition of late apoptosis and inflammation. Transplantation 75:375-382, 2003
26. DE VRIES B, KOHL J, LECLERCQ WK, et al: Complement factor C5a mediates renal ischemia-reperfusion injury independent from neutrophils. J Immunol 170:3883-3889, 2003
27. BUERKE M, SCHWERTZ H, SEITZ W, et al: Novel small molecule inhibitor of C1s exerts cardioprotective effects in ischemia-reperfusion injury in rabbits. J Immunol 167:5375-5380, 2001
28. BUERKE M, PRUFER D, DAHM M, et al: Blocking of classical complement pathway inhibits endothelial adhesion molecule expression and preserves ischemic myocardium from reperfusion injury. J Pharmacol Exp Ther 286:429-438, 1998
29. NIELSEN EW, MOLLNES TE, HARLAN JM, WINN RK: C1-inhibitor reduces the ischaemia-reperfusion injury of skeletal muscles in mice after aortic cross-clamping. Scand J Immunol 56:588-592, 2002
30. PASSWELL J, SCHREINER GF, NONAKA M, et al: Local extrahepatic expression of complement genes C3, factor B, C2, and C4 is increased in murine lupus nephritis. J Clin Invest 82:1676-1684, 1988
31. PASSWELL JH, SCHREINER GF, WETSEL RA, COLTEN HR: Complement gene expression in hepatic and extrahepatic tissues of NZB and NZB x W (F1) mouse strains. Immunology 71:290-294, 1990
32. STURFELT G, NIVED O, SJOHOLM AG: Kinetic analysis of immune complex solubilization: complement function in relation to disease activity in SLE. Clin Exp Rheumatol 10:241-247, 1992
33. RADEKE HH, GESSNER JE, UCIECHOWSKI P, et al: Intrinsic human glomerular mesangial cells can express receptors for IgG complexes (hFc gamma RIII-A) and the associated Fc epsilon RI gamma-chain. J Immunol 153:1281-1292, 1994
34. BOTTO M: C1q knock-out mice for the study of complement deficiency in autoimmune disease. Exp Clin Immunogenet 15:231-234, 1998
35. HOPKEN UE, LU B, GERARD NP, GERARD C: The C5a chemoattractant receptor mediates mucosal defence to infection. Nature 383:86-89, 1996
36. AHEARN JM, FISCHER MB, CROIX D, et al: Disruption of the Cr2 locus results in a reduction in B-1a cells and in an impaired B cell response to T-dependent antigen. Immunity 4:251-262, 1996
37. MATSUMOTO M, FUKUDA W, CIRCOLO A, et al: Abrogation of the alternative complement pathway by targeted deletion of murine factor B. Proc Natl Acad Sci USA 94:8720-8725, 1997
38. TAYLOR PR, NASH JT, THEODORIDIS E, et al: A targeted disruption of the murine complement factor B gene resulting in loss of expression of three genes in close proximity, factor B, C2, and D17H6S45. J Biol Chem 273:1699-1704, 1998
39. SUN X, FUNK CD, DENG C, et al: Role of decay-accelerating factor in regulating complement activation on the erythrocyte surface as revealed by gene targeting. Proc Natl Acad Sci USA 96:628-633, 1999
40. WESSELS MR, BUTKO P, MA M, et al: Studies of group B streptococcal infection in mice deficient in complement component C3 or C4 demonstrate an essential role for complement in both innate and acquired immunity. Proc Natl Acad Sci USA 92:11490-11494, 1995
41. CHEN Z, KORALOV SB, KELSOE G: Complement C4 inhibits systemic autoimmunity through a mechanism independent of complement receptors CR1 and CR2. J Exp Med 192:1339-1352, 2000
42. WALPORT MJ, DAVIES KA, BOTTO M: C1q and systemic lupus erythematosus. Immunobiology 199:265-285, 1998
43. FIGUEROA J, ANDREONI J, DENSEN P: Complement deficiency states and meningococcal disease. Immunol Res 12:295-311, 1993
44. AULT BH: Factor H and the pathogenesis of renal diseases. Pediatr Nephrol 14:1045-1053, 2000
45. PICKERING MC, COOK HT, WARREN J, et al: Uncontrolled C3 activation causes membranoproliferative glomerulonephritis in mice deficient in complement factor H. Nat Genet 31:424-428, 2002
46. WANG Y, HU Q, MADRI JA, et al: Amelioration of lupus-like autoimmune disease in NZB/WF1 mice after treatment with a blocking monoclonal antibody specific for complement component C5. Proc Natl Acad Sci USA 93:8563-8568, 1996